https://www.selleckchem.com/pr....oducts/Sunitinib-Mal
854 -0.353, I =90.3, p0.001). In subgroup analysis a significant reduction was seen among studies with less than four months, upper middle followed by lower middle income countries (LMICs), Western Pacific (WP) followed by Middle Eastern and Northern African (MENA) regions with moderate to substantial heterogeneity. However, there is paucity of studies in underdeveloped countries. Therefore, further studies validated to these contexts are needed to evaluate the DSME effectiveness. PROSPERO database CRD42020124236.
Like
Comment
Share
